CD200 as a prognostic factor in hematological malignancies

Abstract

CD200, an immunoglobulin superfamily membrane protein, is broadly expressed on a variety of cell types and it has structurally similar but clearly defined distribution receptor (CD200R), restricted to cells of the myeloid lineage. results published to date confirmed that signals provided through binding CD200 to a receptor played an important role in the regulation of anti-tumor immunity, including a suppressive effect on T cell-mediated immune response. This glycoprotein was described to be expressed by plasma cells in multiple myeloma and also acute myeloid leukemia blasts, moreover it might be a useful prognostic marker in these disorders. An upregulation of CD200 is a common feature of acute myeloid leukemia or multiple myeloma and is associated with poor outcome, possibly as a result of its immunosuppressive effect on the host immune system. These suggestions about the influence of protein CD200 on regulation of anti-tumor immune response require more precise research, because relatively less is still known about the complex regulation of this process.